P rimary sclerosing cholangitis (PSC) is a progressive autoimmune liver disease characterized by bile duct inflammation and fibrosis. Our understanding of PSC is shaped largely from populations in Europe and the United States that almost exclusively included white patients of Northern European descent. [1] [2] [3] [4] [5] In an ongoing National Institutes of Health-sponsored PSC cohort study of 1000 patients, only 5% of subjects are nonCaucasian. 6 As a result, little is known about PSC in minority populations in the United States, particularly patients of black race, and it is unknown if PSC is a rare disease in patients of black race, or reflects selection bias of sampled cohorts.
Methods
We conducted a cross-sectional study of North American centers participating in the Consortium for Autoimmune Liver Disease. Patients were identified using PSC databases at each center, when available, and/or queries of each center's electronic medical record. PSC diagnosis required cholangiographic (magnetic resonance imaging/magnetic resonance cholangiopancreatography and/or endoscopic retrograde cholangiopancreatography) and/or biopsy evidence of PSC in the absence of secondary causes of PSC. We identified all patients with PSC receiving care at participating centers since 2005, and compared the proportional representation of black patients with PSC at each center with 2010 census data on the black population in the center's metropolitan statistical area (MSA). Race was based on self-report in the medical record. Basic clinical and demographic data on black patients with PSC were collected, and time to transplant, cholangiocarcinoma, or death was evaluated.
Institutional review board approval was obtained at each center, and all data were analyzed in a de-identified fashion.
Results
Among 13 centers, there were 2241 patients with PSC, of whom 193 (8.6%) were black. The centerspecific proportion of PSC patients who were black ranged from 0.7% to 25.7% (Table 1) . For black patients, the median age at diagnosis (excluding the pediatric center) was 38 years (interquartile range, 23-47 y), 51.3% were male, and 58.8% had inflammatory bowel disease (>90% underwent a routine screening colonoscopy). Of the 184 patients with available data on PSC type, 96 (52.2%) had isolated intrahepatic bile duct involvement on cholangiography (<10% had a liver biopsy), 56 (30.4%) had intrahepatic and extrahepatic bile duct involvement, and 6 (3.1%) had small-duct PSC. The incidence rates of the composite end point of transplant, cholangiocarcinoma, or death was 6.58 events/100 person-years (95% CI, 5.30-8.16); the incidence rate of the commonly reported clinical event of transplant or death was 6.31 events per 100 person-years (95% CI, 5.06-7.85) and 0.55 events per 100 person-years (95% CI, 0.26-1.16) for cholangiocarcinoma. 1, 7 The proportional representation of black patients with PSC varied across the 13 centers; for 6 of 13 centers, the ratio of the percentage of PSC patients who were black vs the percentage of residents in the MSA who were black was 0.7 (Table 1) .
Discussion
In this multicenter North American consortium, we show that PSC is not rare among black patients. The proportional representation of PSC in black patients compared with each center's MSA was variable across the 13 centers. Thus, although these data do not show that PSC is as common in black vs white patients, PSC in blacks is not as rare as what would be interpreted based on published data. This suggests that existing literature may reflect selection bias related to the demographics of the underlying population included in these studies, rather than a clinical disease largely restricted to white patients. The existing literature bias could prevent adequate evaluation and diagnosis of PSC in non-white patients by practicing clinicians. We were not able to compare the clinical characteristics of PSC in black vs white patients at each center, but have highlighted potential differences of PSC in black patients compared with published data of solely white patients: (1) 58.8% had inflammatory bowel disease, compared with 75% to 80% in white patients 8 ; (2) 52.2% had isolated intrahepatic bile duct involvement (diagnosed using cholangiograms per American Association for the Study of Liver Diseases guidelines), compared with 20% to 30% in white patients; and (3) 51.3% were male, compared with 60% to 65% in whites. 1 The time from diagnosis to transplant or death was similar to data from published cohort studies of white patients with PSC from tertiary care centers.
1,2,7
We have provided evidence that PSC occurs in black patients and, in this cohort, has unique clinical features. The study had limitations because there was no direct comparator group or systematic evaluation of all included patients, thus validation of these findings is required to compare white vs black patients using detailed clinical data. This may lead to new insights into PSC in general and also particular subphenotypes. Ultimately, these results highlight the need for caution when generalizing findings in rare diseases derived from demographically homogenous groups, and the importance of conducting epidemiologic studies of diverse populations that represent the demographics of the US population. 
